PTC Therapeutics (NASDAQ:PTCT – Get Free Report) will post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect PTC Therapeutics to post earnings of ($1.52) per share for the quarter. PTC Therapeutics has set its FY 2024 guidance at EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.16). The company had revenue of $186.70 million during the quarter, compared to analyst estimates of $192.12 million. On average, analysts expect PTC Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
PTC Therapeutics Price Performance
NASDAQ PTCT opened at $40.66 on Thursday. PTC Therapeutics has a one year low of $17.53 and a one year high of $43.40. The business has a 50 day simple moving average of $36.31 and a 200 day simple moving average of $34.21. The stock has a market capitalization of $3.13 billion, a P/E ratio of -6.57 and a beta of 0.65.
Analysts Set New Price Targets
Get Our Latest Research Report on PTC Therapeutics
PTC Therapeutics Company Profile
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Featured Articles
- Five stocks we like better than PTC Therapeutics
- With Risk Tolerance, One Size Does Not Fit All
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- How to Invest in the Best Canadian StocksĀ
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Ride Out The Recession With These Dividend KingsĀ
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.